MimiVax, Inc. announced today that its Phase 2b clinical trial investigating SurVaxM for glioblastoma has successfully cleared its first interim analysis milestone. The SURVIVE trial (NCT05163080), now fully enrolled, will proceed as planned to evaluate the potential benefits of adding SurVaxM to standard treatment protocols.
The study, conducted across 11 major Cancer Centers in the United States, focuses on patients with newly diagnosed glioblastoma. These patients receive SurVaxM in combination with the current standard of care, which includes surgical resection followed by radiation and chemotherapy.
Mechanism of Action and Therapeutic Potential
SurVaxM represents an innovative approach to glioblastoma treatment, functioning as a peptide mimic immunogen that targets survivin, a critical cell-survival protein. This protein is predominantly found in glioblastoma cells and various other cancer types. The drug works by stimulating the patient's immune system to combat tumor growth and prevent disease recurrence.
Dr. Michael Ciesielski, CEO of MimiVax, expressed optimism about the trial's progress: "We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers."
Trial Design and Oversight
The SURVIVE study's continuation follows a thorough review by the Independent Data Safety Monitoring Committee. While specific details of the interim analysis remain confidential due to FDA regulatory requirements, the trial will proceed without protocol modifications.
The study aims to definitively assess whether the addition of SurVaxM to standard treatment protocols can improve outcomes for glioblastoma patients. This evaluation encompasses multiple aspects, including:
- Safety profile assessment
- Efficacy measurements
- Overall therapeutic benefit
- Integration with standard-of-care treatment
Broader Implications
Given survivin's presence across multiple cancer types, SurVaxM's potential applications could extend beyond glioblastoma. This broader therapeutic potential underscores the significance of the current trial's progress.
MimiVax, a spin-off from Roswell Park Comprehensive Cancer Center, continues to work closely with the FDA while advancing its clinical program. The company maintains its commitment to providing updates at key milestones, adhering strictly to regulatory guidelines throughout the development process.
